Original ResearchCefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients
References (37)
- et al.
Computation of model-independent pharmacokinetic parameters during multiple dosing
J Pharm Sci
(1983) - et al.
Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis
Am J Kidney Dis
(1998) - et al.
Intermittent and continuous ceftazidime infusion for critically ill trauma patients
Am J Surg
(2000) Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
Diagn Microbiol Infect Dis
(1995)- et al.
Estudio nacional de vigilancia de infección nosocomial en unidades de cuidados intensivos. Informe del año 2000
Medicina Intensiva
(2002) - et al.
Cefepime. A review of its antibacterial activity, pharmacokinetic profile and therapeutic use
Drugs
(1994) - et al.
Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins
J Antimicrob Chemother
(1992) Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model
Antimicrob Agents Chemother
(1999)- et al.
Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients
Antimicrob Agents Chemother
(2001) - et al.
Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing
Antimicrob Agents Chemother
(1999)
Pharmacokinetics of cefepime: A review
J Antimicrob Chemother
Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration
Antimicrob Agents Chemother
Reevaluation of formulas for predicting creatinine clearance in adults and children, using compensated creatinine methods
Clin Chem
Bioanalytical method validation—a revisit with a decade of progress
Pharm Res
Guidance for Industry: Bioanalytical Methods Validation for Human Studies
Drug removal during continuous arteriovenous hemofiltration: Theory and clinical observations
Int J Artif Organs
Drug therapy in patients undergoing hemodialysis: Clinical pharmacokinetic considerations
Clin Pharm
Drug administration in critically ill patients with acute renal failure
New Horiz
Cited by (48)
An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy
2022, Journal of Critical CareCitation Excerpt :Body weight was limited to 40 kg as a minimum to assume all patients were adults. It was assumed that all simulated patients are anuric as most critically ill patients receiving CRRT with cefepime or ceftazidime therapy were anuric [21,22,24,25,27-30]. Four conventional cefepime and ceftazidime dosing regimens were simulated: 2-g loading dose (LD) infused over 0.5 h, followed by 1 or 2-g every 8 or 12 h with a 4-h extended-infusion.
Pharmacokinetic variability of beta-lactams in critically ill patients: A narrative review
2020, Anaesthesia Critical Care and Pain MedicineCitation Excerpt :Fig. 1 (flow chart) displays reference selection process, main results of which are shown in Tables 1 and 2. Table 1 summarises 42 studies performed in ICU patients not focusing on RRT [30–73], while Table 2 presents data on patients under RRT from 28 studies [10,74–100]. Vd and Cl variability data were reported for 5 penicillins (amoxicillin, ampicillin, flucloxacillin, piperacillin and temocillin), 3 beta-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam), 6 cephalosporins (cefazolin, cefepime, cefpirome, ceftazidime, ceftriaxone and cefuroxime) and 4 carbapenems (doripenem, ertapenem, imipenem and meropenem).
Antibiotic Dosing in Continuous Renal Replacement Therapy
2017, Advances in Chronic Kidney DiseaseCitation Excerpt :The MCS model integrated relevant input parameters to construct a virtual patient population. Body weight was derived from a large renal replacement therapy study8 and pharmacokinetic data were gathered from published cefepime,35-41 ceftazidime,42-48 levofloxacin,49-52 meropenem,53-59 piperacillin,10,60-65 and tazobactam10,60,61 studies in critically ill patients receiving renal replacement therapy. Antibiotics in this study were chosen based on whether (1) known pharmacokinetic data in CRRT exists, (2) pharmacodynamic target data associated with patient outcomes have been identified, and (3) routine therapeutic drug monitoring are unavailable at most hospitals.
Severe cefepime-induced status epilepticus treated with haemofiltration
2016, Revista Espanola de Anestesiologia y ReanimacionSimultaneous determination of seven β-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies
2014, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCitation Excerpt :On the other hand clearance may be unchanged [17] or decreased [4,18] and in the presence of organ dysfunction such acute kidney injury, diminished clearance may lead to massive accumulation and toxicity [25–27]. In patients with renal dysfunction, optimization antibiotic dosing is further complicated by the use of renal replacement therapy which provides significant and variable extracorporeal clearance for several β-lactams [28–34]. These pharmacokinetic challenges would mean that empiric fixed dose strategy is unlikely to ensure sufficient antibiotic exposure and as well empiric dose optimization is unrealistic due the little data available to guide clinicians.